Vaxart Q2 2023 net loss improves to $22.6M; norovirus Phase 2 data expected Q3

Vaxart, Inc.

Net loss of $22.6M ($0.16 per share) vs $29.4M ($0.23) in Q2 2022.
Revenue of $1.4M from Gates Foundation grant, compared to zero a year ago.
Cash and marketable securities $67.9M; cash runway extended into Q3 2024.
Positive preliminary topline data from Phase 2 bivalent norovirus vaccine; all primary endpoints met.
Topline data from GI.1 norovirus challenge study expected in Q3 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vaxart, Inc. reported the quarter ended June 30, 2023 results: revenue $1.4 million, net income $22.6 million, EPS $0.16.

Period: the quarter ended June 30, 2023
Revenue: $1.4 million
Net income: $22.6 million
EPS: $0.16
Result: reported results

Exact text from the filing

loss per share for the second quarter of 2023 was $0.16, compared to a net loss of $0.23 per share in the second quarter of 2022. ● Revenue for the second quarter of 2023 was $1.4 million, compared to no revenue in the second quarter of 2022. Revenue in the second quarter of 2023 was primarily from revenue recognized for work performed under Vaxart’s grant from

View on SEC.gov

Browse all earnings releases →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-021953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.